This article was originally published in The Gray Sheet
AdvaMed and the Medical Device Manufacturer's Association join a coalition of technology associations in an April 3 letter urging the Securities and Exchange Commission to adopt a draft guidance that would ease external auditing requirements for public companies with annual fiscal revenues under $250 mil. The letter states that "this approach will begin to address the disproportionate cost burdens of section 404 requirements that continue to hamper smaller companies' ability to invest in research and development, to gain access to public capital markets, and to remain competitive." Since it was enacted in 2002, the Sarbanes-Oxley Act has required all public companies to pay to have their internal controls checked by an external auditor (1"The Gray Sheet" Dec. 19, 2005, p. 11)...
You may also be interested in...
A Securities & Exchange Commission committee voiced approval for changes to the Sarbanes-Oxley Act that could save small device firms millions of dollars spent to comply with external auditing requirements
Several years ago, heart device giant Edwards Lifesciences realized it needed a new CAPA framework that shifts corrective and preventive action from a one-size-fits-all method to a more nuanced approach. See what Dan Buehner, director of quality engineering at Edwards Lifesciences, said about it here.
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.